Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

Clinical trial NCT06140732 · UNKNOWN

Trial details

NCT number: NCT06140732
Sponsor: Xuanwu Hospital, Beijing
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chordoma Chemotherapy Effect

Start date: 2023-10-30
Primary completion: 2025-01-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.